ATH 0.00% 0.4¢ alterity therapeutics limited

Ann: Appendix 3B , page-6

  1. 1 Posts.
    It is a reasonable hypothesis that PBT plans a confirmatory trial in Huntington disease that if successful could allow marketing of PBT2 as early as late 2016.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $18.62M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $886 275.3K

Buyers (Bids)

No. Vol. Price($)
48 56368671 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 125986200 26
View Market Depth
Last trade - 11.34am 30/08/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.